Spyryx Presents Data Ably Supporting SPX-101 as Potential Treatment for All CF Patients
Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate...
Sclerosis medicine can fight multi-resistant bacteria
A surprising discovery shows that a widely used and 20-year-old medicine used to treat multiple sclerosis can also beat a type of...
Virtual reality used during cystic fibrosis treatment
Virtual reality headsets like this one allow the viewer to immerse themselves in another setting Virtual reality headsets are being used...
Tezacaftor-ivacaftor improves pulmonary function in cystic fibrosis patients: The EVOLVE trial
1. Tezacaftor-Ivacaftor significantly improves lung function and reduces the frequency of pulmonary exacerbations in cystic fibrosis (CF)...
CF Patients Increase Bacterial Load But Lose Bacterial Diversity As They Age, Study Finds
Cystic fibrosis (CF) patients have more bacteria but lower bacterial diversity in their lungs than people without CF — yet bacterial...
Commission approves medical marijuana facilities
Stratford could eventually have two medical marijuana dispensaries in town, based on a Zoning Commission vote at the Nov. 14 meeting...
Case Report Provides New Insights on Dosing of Novel Drug for Patients with Cystic Fibrosis
Ceftolozane/tazobactam is safe, effective, and well-tolerated in the treatment of multidrug-resistant Pseudomonas aeruginosa infection...
Europe’s CHMP Gives Its Blessing to Vertex’s Orkambi as CF Therapy for Younger Children
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Orkambi...
